German Court Grants PIs Preventing Marketing of Aflibercept Biosimilars by STADA, Hexal, Celltrion and Advanz Pharma
On 8 January 2026, the Munich Regional Court granted Regeneron and Bayer preliminary injunctions (PIS) preventing STADA, Hexal, Celltrion and Advanz…
Pearce IP is Australia and New Zealand’s leading life sciences-focused intellectual property law firm.
Supporting life sciences clients from early-stage R&D through to commercial launch and beyond.
pearceIP.law | [email protected] | +61 2 9023 9988 | +64 4 886 1199
Popular articles from this firm
